Metabolic and bariatric surgery and obesity pharmacotherapy for cancer prevention: Current status and future possibilities

Mary C. Playdon; Sheetal Hardikar; Prasoona Karra; Rachel Hoobler; Anna R. Ibele; Katherine L. Cook; Amanika Kumar; Joseph E. Ippolito; Justin C. Brown

doi:10.1093/jncimonographs/lgad003

Metabolic and bariatric surgery and obesity pharmacotherapy for cancer prevention: Current status and future possibilities

Mary C. Playdon, Sheetal Hardikar, Prasoona Karra, Rachel Hoobler, Anna R. Ibele, Katherine L. Cook, Amanika Kumar, Joseph E. Ippolito, Justin C. Brown

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Obesity is a chronic, relapsing, progressive disease of excess adiposity that increases the risk of developing at least 13 types of cancer. This report provides a concise review of the current state of the science regarding metabolic and bariatric surgery and obesity pharmacotherapy related to cancer risk. Meta-analyses of cohort studies report that metabolic and bariatric surgery is independently associated with a lower risk of incident cancer than nonsurgical obesity care. Less is known regarding the cancer-preventive effects of obesity pharmacotherapy. The recent approval and promising pipeline of obesity drugs will provide the opportunity to understand the potential for obesity therapy to emerge as an evidence-based cancer prevention strategy. There are myriad research opportunities to advance our understanding of how metabolic and bariatric surgery and obesity pharmacotherapy may be used for cancer prevention.

Original language	English
Pages (from-to)	68-76
Number of pages	9
Journal	Journal of the National Cancer Institute - Monographs
Volume	2023
Issue number	61
DOIs	https://doi.org/10.1093/jncimonographs/lgad003
State	Published - Jun 1 2023

Access to Document

10.1093/jncimonographs/lgad003

Cite this

Playdon, M. C., Hardikar, S., Karra, P., Hoobler, R., Ibele, A. R., Cook, K. L., Kumar, A., Ippolito, J. E., & Brown, J. C. (2023). Metabolic and bariatric surgery and obesity pharmacotherapy for cancer prevention: Current status and future possibilities. Journal of the National Cancer Institute - Monographs, 2023(61), 68-76. https://doi.org/10.1093/jncimonographs/lgad003

@article{696e3f3be0d44015831d51ab6ce157c6,

title = "Metabolic and bariatric surgery and obesity pharmacotherapy for cancer prevention: Current status and future possibilities",

abstract = "Obesity is a chronic, relapsing, progressive disease of excess adiposity that increases the risk of developing at least 13 types of cancer. This report provides a concise review of the current state of the science regarding metabolic and bariatric surgery and obesity pharmacotherapy related to cancer risk. Meta-analyses of cohort studies report that metabolic and bariatric surgery is independently associated with a lower risk of incident cancer than nonsurgical obesity care. Less is known regarding the cancer-preventive effects of obesity pharmacotherapy. The recent approval and promising pipeline of obesity drugs will provide the opportunity to understand the potential for obesity therapy to emerge as an evidence-based cancer prevention strategy. There are myriad research opportunities to advance our understanding of how metabolic and bariatric surgery and obesity pharmacotherapy may be used for cancer prevention.",

author = "Playdon, {Mary C.} and Sheetal Hardikar and Prasoona Karra and Rachel Hoobler and Ibele, {Anna R.} and Cook, {Katherine L.} and Amanika Kumar and Ippolito, {Joseph E.} and Brown, {Justin C.}",

year = "2023",

month = jun,

day = "1",

doi = "10.1093/jncimonographs/lgad003",

language = "English",

volume = "2023",

pages = "68--76",

journal = "Journal of the National Cancer Institute - Monographs",

issn = "1052-6773",

number = "61",

}

TY - JOUR

T1 - Metabolic and bariatric surgery and obesity pharmacotherapy for cancer prevention

T2 - Current status and future possibilities

AU - Playdon, Mary C.

AU - Hardikar, Sheetal

AU - Karra, Prasoona

AU - Hoobler, Rachel

AU - Ibele, Anna R.

AU - Cook, Katherine L.

AU - Kumar, Amanika

AU - Ippolito, Joseph E.

AU - Brown, Justin C.

PY - 2023/6/1

Y1 - 2023/6/1

N2 - Obesity is a chronic, relapsing, progressive disease of excess adiposity that increases the risk of developing at least 13 types of cancer. This report provides a concise review of the current state of the science regarding metabolic and bariatric surgery and obesity pharmacotherapy related to cancer risk. Meta-analyses of cohort studies report that metabolic and bariatric surgery is independently associated with a lower risk of incident cancer than nonsurgical obesity care. Less is known regarding the cancer-preventive effects of obesity pharmacotherapy. The recent approval and promising pipeline of obesity drugs will provide the opportunity to understand the potential for obesity therapy to emerge as an evidence-based cancer prevention strategy. There are myriad research opportunities to advance our understanding of how metabolic and bariatric surgery and obesity pharmacotherapy may be used for cancer prevention.

AB - Obesity is a chronic, relapsing, progressive disease of excess adiposity that increases the risk of developing at least 13 types of cancer. This report provides a concise review of the current state of the science regarding metabolic and bariatric surgery and obesity pharmacotherapy related to cancer risk. Meta-analyses of cohort studies report that metabolic and bariatric surgery is independently associated with a lower risk of incident cancer than nonsurgical obesity care. Less is known regarding the cancer-preventive effects of obesity pharmacotherapy. The recent approval and promising pipeline of obesity drugs will provide the opportunity to understand the potential for obesity therapy to emerge as an evidence-based cancer prevention strategy. There are myriad research opportunities to advance our understanding of how metabolic and bariatric surgery and obesity pharmacotherapy may be used for cancer prevention.

UR - http://www.scopus.com/inward/record.url?scp=85159544630&partnerID=8YFLogxK

U2 - 10.1093/jncimonographs/lgad003

DO - 10.1093/jncimonographs/lgad003

M3 - Article

C2 - 37139980

AN - SCOPUS:85159544630

SN - 1052-6773

VL - 2023

SP - 68

EP - 76

JO - Journal of the National Cancer Institute - Monographs

JF - Journal of the National Cancer Institute - Monographs

IS - 61

ER -

Metabolic and bariatric surgery and obesity pharmacotherapy for cancer prevention: Current status and future possibilities

Abstract

Access to Document

Other files and links

Fingerprint

Cite this